Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 335

1.

α2-Adrenoceptors in the treatment of major neuropsychiatric disorders.

Langer SZ.

Trends Pharmacol Sci. 2015 Apr;36(4):196-202. doi: 10.1016/j.tips.2015.02.006. Epub 2015 Mar 13. Review.

PMID:
25771972
2.

Therapeutic use of release-modifying drugs.

Langer SZ.

Handb Exp Pharmacol. 2008;(184):561-73. Review.

PMID:
18064425
3.

Presynaptic autoreceptors regulating transmitter release.

Langer SZ.

Neurochem Int. 2008 Jan;52(1-2):26-30. Epub 2007 May 16. Review.

PMID:
17583385
4.

Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins.

David A, Mabjeesh N, Azar I, Biton S, Engel S, Bernstein J, Romano J, Avidor Y, Waks T, Eshhar Z, Langer SZ, Lifschitz-Mercer B, Matzkin H, Rotman G, Toporik A, Savitsky K, Mintz L.

J Biol Chem. 2002 May 17;277(20):18084-90. Epub 2002 Feb 7.

5.

Role of alpha1-adrenoceptors in the future treatment of urological diseases.

Langer SZ, Kirby R, Wyllie MG, Clarke DE, Andersson KE, Chapple C.

Eur Urol. 1999;36 Suppl 1:66-7. No abstract available.

PMID:
10438242
6.

History and nomenclature of alpha1-adrenoceptors.

Langer SZ.

Eur Urol. 1999;36 Suppl 1:2-6.

PMID:
10438241
7.

History and nomenclature of alpha1-adrenoceptors

Langer SZ.

Eur Urol. 1999;36 Suppl 1:2-6.

PMID:
10393465
8.

Dysthymia: clinical picture, extent of overlap with chronic fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas.

Brunello N, Akiskal H, Boyer P, Gessa GL, Howland RH, Langer SZ, Mendlewicz J, Paes de Souza M, Placidi GF, Racagni G, Wessely S.

J Affect Disord. 1999 Jan-Mar;52(1-3):275-90. Review.

PMID:
10357046
9.

Development of an inducible NMDA receptor stable cell line with an intracellular Ca2+ reporter.

Renard S, Drouet-Pétré C, Partiseti M, Langer SZ, Graham D, Besnard F.

Eur J Pharmacol. 1999 Feb 5;366(2-3):319-28.

PMID:
10082214
10.

International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function.

Barnard EA, Skolnick P, Olsen RW, Mohler H, Sieghart W, Biggio G, Braestrup C, Bateson AN, Langer SZ.

Pharmacol Rev. 1998 Jun;50(2):291-313. Review. No abstract available.

11.

Nomenclature and state of the art on alpha1-adrenoceptors.

Langer SZ.

Eur Urol. 1998;33 Suppl 2:2-6. Review.

PMID:
9556189
12.
13.

Role of the alpha-adrenoceptor in regulating noradrenaline overflow by nerve stimulation. 1971.

Enero MA, Langer SZ, Rothlin RP, Stefano FJ.

Br J Pharmacol. 1997 Feb;120(4 Suppl):361-77; discussion 358-60. No abstract available.

14.

Practical issues in clinical research of schizophrenia.

Brunello N, Judd LL, Langer SZ, Mendlewicz J, Racagni G.

Neuropsychobiology. 1997;35(2):57-60. No abstract available.

PMID:
9097292
15.

GABAA receptor subtype diversity: implications for new generation hypnotic drug discovery.

Graham D, Besnard F, Faure C, Langer SZ.

Sleep. 1996 Oct;19(8 Suppl):S43-54. No abstract available.

PMID:
8958637
16.

Effects of zolpidem on local cerebral glucose metabolism during non-REM sleep in normal volunteers: a positron emission tomography study.

Gillin JC, Buchsbaum MS, Valladares-Neto DC, Hong CC, Hazlett E, Langer SZ, Wu J.

Neuropsychopharmacology. 1996 Sep;15(3):302-13.

17.

Pharmacological characterization of the cloned human 5-hydroxytryptamine transporter.

Agnel M, Esnaud H, Langer SZ, Graham D.

Biochem Pharmacol. 1996 May 3;51(9):1145-51.

PMID:
8645336
18.

Pharmacological profile of benzodiazepine site ligands with recombinant GABAA receptor subtypes.

Graham D, Faure C, Besnard F, Langer SZ.

Eur Neuropsychopharmacol. 1996 May;6(2):119-25.

PMID:
8791037
19.
20.

Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytes.

Avenet P, Léonardon J, Besnard F, Graham D, Frost J, Depoortere H, Langer SZ, Scatton B.

Eur J Pharmacol. 1996 Jan 25;296(2):209-13.

PMID:
8838458
21.

Quantification of alpha 1-adrenoceptor subtypes in human tissues by competitive RT-PCR analysis.

Faure C, Gouhier C, Langer SZ, Graham D.

Biochem Biophys Res Commun. 1995 Aug 24;213(3):935-43.

PMID:
7654257
22.

Further evidence that the classical alpha 1A- and cloned alpha 1c-adrenoceptors are the same subtype.

Pimoule C, Langer SZ, Graham D.

Eur J Pharmacol. 1995 Jun 23;290(1):49-53.

PMID:
7664824
23.

Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin.

Granger P, Biton B, Faure C, Vige X, Depoortere H, Graham D, Langer SZ, Scatton B, Avenet P.

Mol Pharmacol. 1995 Jun;47(6):1189-96.

PMID:
7603459
24.

International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update.

Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ, Minneman KP, Ruffolo RR Jr.

Pharmacol Rev. 1995 Jun;47(2):267-70. Review. No abstract available.

PMID:
7568329
25.

Binding of [3H]cirazoline to an imidazoline site in rat brain and kidney membranes.

Le Rouzic M, Angel I, Schoemaker H, Allen J, Arbilla S, Langer SZ.

Eur J Pharmacol. 1995 May 24;278(3):261-4.

PMID:
7589165
26.

In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent.

Benavides J, Schoemaker H, Dana C, Claustre Y, Delahaye M, Prouteau M, Manoury P, Allen J, Scatton B, Langer SZ, et al.

Arzneimittelforschung. 1995 May;45(5):551-8.

PMID:
7612054
27.

Expression of alpha 1-adrenoceptor subtypes in rat tissues: implications for alpha 1-adrenoceptor classification.

Faure C, Pimoule C, Arbilla S, Langer SZ, Graham D.

Eur J Pharmacol. 1994 Jul 15;268(2):141-9.

PMID:
7957636
28.

International Union of Pharmacology nomenclature of adrenoceptors.

Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR Jr, Trendelenburg U.

Pharmacol Rev. 1994 Jun;46(2):121-36. Review. No abstract available.

PMID:
7938162
29.

In vitro stimulation of insulin release by SL 84.0418, a new alpha 2-adrenoceptor antagonist.

Jonas JC, Plant TD, Angel I, Langer SZ, Henquin JC.

Eur J Pharmacol. 1994 Mar 11;254(1-2):27-33.

PMID:
7911430
30.

Identification of alpha 1-adrenoceptor subtypes present in the human prostate.

Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D.

Life Sci. 1994;54(21):1595-605.

PMID:
8196478
31.

Expression and properties of recombinant alpha 1 beta 2 gamma 2 and alpha 5 beta 2 gamma 2 forms of the rat GABAA receptor.

Faure-Halley C, Graham D, Arbilla S, Langer SZ.

Eur J Pharmacol. 1993 Aug 15;246(3):283-7.

PMID:
8223951
32.

Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract.

Lefèvre-Borg F, O'Connor SE, Schoemaker H, Hicks PE, Lechaire J, Gautier E, Pierre F, Pimoule C, Manoury P, Langer SZ.

Br J Pharmacol. 1993 Aug;109(4):1282-9.

33.

In vivo pharmacological profile of SL 84.0418, a new selective, peripherally active alpha 2-adrenoceptor antagonist.

Angel I, Grosset A, Perrault G, Schoemaker H, Langer SZ.

Eur J Pharmacol. 1993 Apr 6;234(2-3):137-45.

PMID:
8097719
34.

Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties.

Angel I, Schoemaker H, Prouteau M, Garreau M, Langer SZ.

Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45.

PMID:
8385615
35.
36.

SL 84.0418: a novel, potent and selective alpha-2 adrenoceptor antagonist: in vitro pharmacological profile.

Angel I, Schoemaker H, Arbilla S, Galzin AM, Berry C, Niddam R, Pimoule C, Sevrin M, Wick A, Langer SZ.

J Pharmacol Exp Ther. 1992 Dec;263(3):1327-33.

PMID:
1281878
37.

Characterization of the 5-hydroxytryptamine receptor modulating the release of 5-[3H]hydroxytryptamine in slices of the human neocortex.

Galzin AM, Poirier MF, Lista A, Chodkiewicz JP, Blier P, Ramdine R, Loô H, Roux FX, Redondo A, Langer SZ.

J Neurochem. 1992 Oct;59(4):1293-301.

PMID:
1357094
38.
39.
40.

Adrenergic and nonadrenergic cotransmitters inhibit insulin secretion during sympathetic stimulation in dogs.

Lorrain J, Angel I, Duval N, Eon MT, Oblin A, Langer SZ.

Am J Physiol. 1992 Jul;263(1 Pt 1):E72-8.

PMID:
1353301
41.

Advances in sodium-ion coupled biogenic amine transporters.

Graham D, Langer SZ.

Life Sci. 1992;51(9):631-45. Review.

PMID:
1501510
42.

The serotonin re-uptake transporter as a target for antidepressant action.

Langer SZ, Graham D, Arbilla S, Schoemaker H, Angel I.

Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:436A-437A. No abstract available.

PMID:
1498906
43.

The role of noradrenergic transmission in the mechanism of action of classical and novel antidepressant drugs.

Langer SZ, Graham D, Pimoule C, Arbilla S.

Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:317A-318A. No abstract available.

PMID:
1323394
44.

Characterization and purification of the neuronal sodium-ion-coupled 5-hydroxytryptamine transporter.

Graham D, Esnaud H, Langer SZ.

Biochem Soc Trans. 1991 Feb;19(1):99-102.

PMID:
1828051
45.

Pre- and postsynaptic alpha-2 adrenoceptors as target for drug discovery.

Langer SZ, Angel I.

J Neural Transm Suppl. 1991;34:171-7.

PMID:
1687782
46.
47.

Involvement of alpha-2 adrenergic receptor subtypes in hyperglycemia.

Angel I, Niddam R, Langer SZ.

J Pharmacol Exp Ther. 1990 Sep;254(3):877-82.

PMID:
1975624
48.

Interaction between serotonin uptake inhibitors and alpha-2 adrenergic heteroreceptors in the rat hypothalamus.

Blier P, Galzin AM, Langer SZ.

J Pharmacol Exp Ther. 1990 Jul;254(1):236-44.

PMID:
2164092
49.

Selectivity for omega-receptor subtypes as a strategy for the development of anxiolytic drugs.

Langer SZ, Arbilla S, Tan S, Lloyd KG, George P, Allen J, Wick AE.

Pharmacopsychiatry. 1990 May;23 Suppl 3:103-7. Review.

PMID:
1974068
50.

Binding of [3H]ifenprodil, a novel NMDA antagonist, to a polyamine-sensitive site in the rat cerebral cortex.

Schoemaker H, Allen J, Langer SZ.

Eur J Pharmacol. 1990 Feb 6;176(2):249-50. No abstract available.

PMID:
2178949

Supplemental Content

Loading ...
Support Center